{"component": "clause", "props": {"groups": [{"samples": [{"hash": "gfddRBCZBev", "uri": "/contracts/gfddRBCZBev#milestone-payment", "label": "Asset Purchase and License Agreement (Eton Pharmaceuticals, Inc.)", "score": 29.6050643921, "published": true}, {"hash": "5ocWiTfh46G", "uri": "/contracts/5ocWiTfh46G#milestone-payment", "label": "Asset Purchase and License Agreement (Eton Pharmaceuticals, Inc.)", "score": 29.6050643921, "published": true}, {"hash": "eXp8i6LIdYO", "uri": "/contracts/eXp8i6LIdYO#milestone-payment", "label": "Asset Purchase and License Agreement (Eton Pharmaceuticals, Inc.)", "score": 29.4873371124, "published": true}], "snippet": "Within thirty (30) days following the first Patent Issuance, Eton shall give written notice to Imprimis and shall pay to Imprimis a non-refundable and noncreditable payment of fifty thousand dollars ($50,000).", "snippet_links": [{"key": "within-thirty", "type": "clause", "offset": [0, 13]}, {"key": "following-the", "type": "definition", "offset": [24, 37]}, {"key": "patent-issuance", "type": "definition", "offset": [44, 59]}, {"key": "notice-to", "type": "clause", "offset": [85, 94]}, {"key": "pay-to", "type": "definition", "offset": [114, 120]}, {"key": "a-non", "type": "clause", "offset": [130, 135]}, {"key": "payment-of", "type": "clause", "offset": [165, 175]}], "size": 6, "hash": "17e3676018c8c0d2ef81198450719f8a", "id": 1}, {"samples": [{"hash": "bmJ8Gy4ixDC", "uri": "/contracts/bmJ8Gy4ixDC#milestone-payment", "label": "Confidentiality Agreement (Furiex Pharmaceuticals, Inc.)", "score": 21.3997268677, "published": true}, {"hash": "bhaPvRe5nZr", "uri": "/contracts/bhaPvRe5nZr#milestone-payment", "label": "Confidentiality Agreement (Furiex Pharmaceuticals, Inc.)", "score": 21.1478443146, "published": true}, {"hash": "dRb136kry7", "uri": "/contracts/dRb136kry7#milestone-payment", "label": "Confidentiality Agreement (Pharmaceutical Product Development Inc)", "score": 21.0, "published": true}], "snippet": "First dosing of any Product to a subject in a Phase III Trial Fifteen million dollars ($15,000,000) [*] [*] million dollars ($[*]) [*] [*] million dollars ($[*]) [*] [*] million dollars ($[*]) [*] [*] million dollars ($[*]) [*] [*] million dollars ($[*]) [*] [*] million [*] thousand dollars ($[*]) [*] Confidential treatment requested; certain information omitted and filed separately with the SEC.", "snippet_links": [{"key": "first-dosing", "type": "definition", "offset": [0, 12]}, {"key": "phase-iii-trial", "type": "definition", "offset": [46, 61]}, {"key": "confidential-treatment-requested", "type": "definition", "offset": [303, 335]}, {"key": "certain-information", "type": "clause", "offset": [337, 356]}, {"key": "the-sec", "type": "definition", "offset": [391, 398]}], "size": 6, "hash": "80c37a007502813ba2aecd62f4409af4", "id": 2}, {"samples": [{"hash": "bsDKMRZ3B6F", "uri": "/contracts/bsDKMRZ3B6F#milestone-payment", "label": "Asset Purchase Agreement (Zogenix, Inc.)", "score": 21.8186168671, "published": true}, {"hash": "lycq0F3Lj0k", "uri": "/contracts/lycq0F3Lj0k#milestone-payment", "label": "Asset Purchase Agreement (Zogenix, Inc.)", "score": 21.6707725525, "published": true}, {"hash": "dyVmNxFOIUu", "uri": "/contracts/dyVmNxFOIUu#milestone-payment", "label": "Asset Purchase Agreement (Zogenix Inc)", "score": 20.0, "published": true}], "snippet": "Purchaser shall pay Aradigm $4,000,000 within 30 days of the first U.S. commercial sale of the Sumatriptan Product.", "snippet_links": [{"key": "sale-of-the", "type": "clause", "offset": [83, 94]}, {"key": "sumatriptan-product", "type": "definition", "offset": [95, 114]}], "size": 5, "hash": "e0dfd727209cd9638e90b1680ca2390a", "id": 5}, {"samples": [{"hash": "6HTQseXwE8e", "uri": "/contracts/6HTQseXwE8e#milestone-payment", "label": "Extended Collaboration and License Agreement (BTHC VI Inc)", "score": 21.0, "published": true}, {"hash": "5u4GMfmN1Md", "uri": "/contracts/5u4GMfmN1Md#milestone-payment", "label": "Extended Collaboration and License Agreement (Athersys, Inc / New)", "score": 21.0, "published": true}], "snippet": "Filing of first IND for the Candidate Compound directed against a designated target expressed by an Accepted Cell Line $[*] Initiation of first Phase II clinical study for the Candidate Compound $[*] Initiation of first Phase III clinical study for the Candidate Compound $[*] Approval of a Product containing the Candidate Compound by Food and Drug Administration as drug $[*] As used in this Exhibit B, the phrase \u201cInitiation of first Phase III clinical study\u201d shall be deemed to include, if a party conducts a Phase II/III study on a Candidate Compound, the point during such Phase II/III clinical trial when the party conducting the trial has the regulatory approval to proceed with such trial as a pivotal trial. BMS shall promptly notify Athersys of the first occurrence of any milestone with respect to each Candidate Compound. Milestone payments shall be made only once with respect to any given Candidate Compound, regardless of the number of indications sought (or approvals obtained) with respect to such Candidate Compound, whether alone or in combination with other compounds or products, and regardless of any new dosage strengths, preparations or forms of administration for such Candidate Compound. If BMS develops as a back-up Candidate Compound that inhibits or otherwise modulates the activity of a particular molecular target of a Candidate Compound on which BMS is already making milestone payments, then BMS may conduct clinical development on such back-up or follow-on Candidate Compounds and shall not be obligated to make any milestone payments with respect to any such back-up or follow-on Candidate Compound, except as otherwise provided below. In the event that a particular Candidate Compound is dropped from active clinical development work or marketing for safety or efficacy reasons and is specifically replaced with a different Candidate Compound targeting the same molecular target as such dropped Candidate Compound, such new Candidate Compound shall be deemed a \u201cReplacement Compound.\u201d BMS shall not be obligated to make milestone payments that were earlier made with respect to a dropped Candidate Compound and replaced by a Replacement Compound, but, subject to the preceding paragraph, BMS shall pay all milestone payments for milestone events achieved by such Replacement Compound that had not been achieved by such dropped Candidate Compound.", "snippet_links": [{"key": "candidate-compound", "type": "definition", "offset": [28, 46]}, {"key": "directed-against", "type": "definition", "offset": [47, 63]}, {"key": "designated-target", "type": "definition", "offset": [66, 83]}, {"key": "accepted-cell-line", "type": "definition", "offset": [100, 118]}, {"key": "phase-ii-clinical-study", "type": "definition", "offset": [144, 167]}, {"key": "phase-iii-clinical-study", "type": "definition", "offset": [220, 244]}, {"key": "approval-of", "type": "clause", "offset": [277, 288]}, {"key": "food-and-drug-administration", "type": "definition", "offset": [336, 364]}, {"key": "exhibit-b", "type": "definition", "offset": [394, 403]}, {"key": "the-phrase", "type": "definition", "offset": [405, 415]}, {"key": "a-party", "type": "clause", "offset": [494, 501]}, {"key": "a-phase", "type": "definition", "offset": [511, 518]}, {"key": "clinical-trial", "type": "clause", "offset": [592, 606]}, {"key": "the-party", "type": "clause", "offset": [612, 621]}, {"key": "the-trial", "type": "clause", "offset": [633, 642]}, {"key": "approval-to-proceed", "type": "clause", "offset": [662, 681]}, {"key": "pivotal-trial", "type": "definition", "offset": [703, 716]}, {"key": "promptly-notify", "type": "clause", "offset": [728, 743]}, {"key": "first-occurrence", "type": "definition", "offset": [760, 776]}, {"key": "with-respect-to", "type": "clause", "offset": [794, 809]}, {"key": "payments-shall-be", "type": "clause", "offset": [845, 862]}, {"key": "number-of", "type": "clause", "offset": [942, 951]}, {"key": "in-combination", "type": "definition", "offset": [1053, 1067]}, {"key": "other-compounds", "type": "clause", "offset": [1073, 1088]}, {"key": "regardless-of-any", "type": "clause", "offset": [1106, 1123]}, {"key": "the-activity", "type": "definition", "offset": [1300, 1312]}, {"key": "molecular-target", "type": "definition", "offset": [1329, 1345]}, {"key": "except-as-otherwise-provided", "type": "clause", "offset": [1636, 1664]}, {"key": "in-the-event", "type": "clause", "offset": [1672, 1684]}, {"key": "development-work", "type": "clause", "offset": [1754, 1770]}, {"key": "for-safety", "type": "clause", "offset": [1784, 1794]}, {"key": "replaced-with", "type": "clause", "offset": [1835, 1848]}, {"key": "replacement-compound", "type": "definition", "offset": [1999, 2019]}, {"key": "subject-to-the", "type": "clause", "offset": [2189, 2203]}, {"key": "milestone-payments-for", "type": "clause", "offset": [2243, 2265]}, {"key": "milestone-events", "type": "definition", "offset": [2266, 2282]}], "size": 4, "hash": "76b4605ecb6192c3774ef416158bac01", "id": 10}, {"samples": [{"hash": "1RPlgRUGH93", "uri": "/contracts/1RPlgRUGH93#milestone-payment", "label": "Termination and Transition Agreement", "score": 31.3408622742, "published": true}, {"hash": "R1sQfbTmJx", "uri": "/contracts/R1sQfbTmJx#milestone-payment", "label": "Termination and Transition Agreement (NPS Pharmaceuticals Inc)", "score": 24.2114982605, "published": true}], "snippet": "Within fifty (50) days after the Sales Milestone Date (subject to Section 7.1(c)), NPS shall make a one-time payment to Takeda equal to thirty million dollars (US$30,000,000) (such payment, the \u201cMilestone Payment\u201d). NPS\u2019s obligation to make the Milestone Payment shall accelerate and be due within fifty (50) days after the occurrence of a Qualifying Change of Control. The Milestone Payment shall be in the form of either or a combination of (x) a wire transfer of immediately available funds to an account designated by Takeda, and/or (y) if the NPS Common Stock is publicly traded on a Trading Market, at NPS\u2019s sole discretion (but subject to the limitations set forth in Section 7.3), the issuance and sale to Takeda GmbH and Takeda Pharma of such number of shares of NPS Common Stock (or shares of common stock of NPS\u2019 successor or such successor\u2019s parent in the event of an acceleration of the Milestone Payment obligation due to a Qualifying Change of Control if the common stock of such successor or such successor\u2019s parent is publicly traded on a Trading Market), equal to the quotient of (A) thirty million dollars (US$30,000,000) divided by (B) the VWAP of the NPS Common Stock (or common stock of NPS\u2019 successor or such successor\u2019s parent in the event of an acceleration of the Milestone Payment obligation due to a Qualifying Change of Control, as applicable) over the thirty trading (30) days immediately prior to (but not including) the Sales Milestone Date or the date of the Qualifying Change of Control, as applicable (such shares, the \u201cMilestone Shares\u201d, and together with the Initial Consideration Shares, the \u201cShares\u201d). The total number of Milestone Shares shall be allocated between Takeda GmbH and Takeda Pharma in such amounts as shall be notified by Takeda to NPS. If NPS elects to pay the Milestone Payment in the form of Milestone Shares, NPS shall give Takeda written notice of such election at least thirty (30) days before the date NPS wishes to effect the closing of the issuance and sale of the Milestone Shares as contemplated by this Section 7.2 (such closing, the \u201cMilestone Shares Closing\u201d). The Milestone Shares Closing shall take place on or before the date mutually agreed by NPS and Takeda, which date shall be not later than the end of the fifty (50) day period referenced in the first or second sentence of this Section, as applicable (or in the last sentence of Section 7.1(c), if applicable) (the date of the Milestone Shares Closing is referred to herein as the \u201cMilestone Shares Closing Date\u201d).", "snippet_links": [{"key": "days-after", "type": "definition", "offset": [18, 28]}, {"key": "milestone-date", "type": "definition", "offset": [39, 53]}, {"key": "subject-to-section", "type": "clause", "offset": [55, 73]}, {"key": "payment-to", "type": "clause", "offset": [109, 119]}, {"key": "equal-to", "type": "definition", "offset": [127, 135]}, {"key": "obligation-to", "type": "clause", "offset": [222, 235]}, {"key": "qualifying-change-of-control", "type": "definition", "offset": [340, 368]}, {"key": "form-of", "type": "definition", "offset": [408, 415]}, {"key": "transfer-of", "type": "definition", "offset": [454, 465]}, {"key": "immediately-available-funds", "type": "definition", "offset": [466, 493]}, {"key": "by-takeda", "type": "clause", "offset": [519, 528]}, {"key": "publicly-traded", "type": "clause", "offset": [568, 583]}, {"key": "trading-market", "type": "clause", "offset": [589, 603]}, {"key": "sole-discretion", "type": "definition", "offset": [614, 629]}, {"key": "subject-to-the", "type": "clause", "offset": [635, 649]}, {"key": "section-73", "type": "clause", "offset": [675, 686]}, {"key": "the-issuance-and-sale", "type": "clause", "offset": [689, 710]}, {"key": "number-of-shares-of", "type": "clause", "offset": [752, 771]}, {"key": "shares-of-common-stock", "type": "clause", "offset": [793, 815]}, {"key": "in-the-event-of", "type": "definition", "offset": [861, 876]}, {"key": "payment-obligation", "type": "definition", "offset": [910, 928]}, {"key": "the-common-stock", "type": "clause", "offset": [970, 986]}, {"key": "divided-by", "type": "clause", "offset": [1141, 1151]}, {"key": "prior-to", "type": "clause", "offset": [1419, 1427]}, {"key": "date-of", "type": "clause", "offset": [1480, 1487]}, {"key": "milestone-shares", "type": "clause", "offset": [1555, 1571]}, {"key": "initial-consideration-shares", "type": "clause", "offset": [1596, 1624]}, {"key": "total-number-of", "type": "definition", "offset": [1645, 1660]}, {"key": "to-pay", "type": "clause", "offset": [1804, 1810]}, {"key": "notice-of", "type": "definition", "offset": [1896, 1905]}, {"key": "closing-of-the-issuance", "type": "clause", "offset": [1987, 2010]}, {"key": "sale-of-the", "type": "clause", "offset": [2015, 2026]}, {"key": "section-72", "type": "clause", "offset": [2068, 2079]}, {"key": "shares-closing", "type": "clause", "offset": [2110, 2124]}, {"key": "agreed-by", "type": "clause", "offset": [2205, 2214]}, {"key": "day-period", "type": "definition", "offset": [2292, 2302]}, {"key": "the-last-sentence", "type": "clause", "offset": [2384, 2401]}, {"key": "if-applicable", "type": "definition", "offset": [2421, 2434]}, {"key": "closing-date", "type": "clause", "offset": [2525, 2537]}], "size": 5, "hash": "e527d9dd1282e2c0f1ed3575b7a94be1", "id": 6}, {"samples": [{"hash": "fqDNGJUWNf7", "uri": "/contracts/fqDNGJUWNf7#milestone-payment", "label": "Asset Purchase Agreement", "score": 31.3408622742, "published": true}, {"hash": "6UlEU2ujogQ", "uri": "/contracts/6UlEU2ujogQ#milestone-payment", "label": "Asset Purchase Agreement (Cerecor Inc.)", "score": 28.6167011261, "published": true}], "snippet": "(a) Subject to the terms and conditions of this Agreement and in further consideration of the sale, conveyance, delivery, transfer and assignment of the Purchased Assets to Buyer and Seller\u2019s other convents and obligations hereunder, Buyer shall make a one-time, non-refundable, non-creditable milestone payment of $20,000,000 to Seller upon the filing and acceptance of an NDA for, or other equivalent application to sell, a Product in the United States (the \u201cMilestone Payment\u201d).\n(b) Buyer shall notify Seller in writing within 10 Business Days after the achievement of the milestone described in Section 2.5(a) above by Buyer or any of its Affiliates, and Buyer shall pay Seller the Milestone Payment on the date the first milestone payment described under \u201cMilestone Event\u201d in Section 7.02(a) of the License Agreement is due, and in any event not later than 60 days after such notification to Seller. Payment of the Milestone Payment to Seller shall be made by wire transfer of immediately available funds to the account set forth on Schedule 2.1(b)(i) or otherwise specified in writing by Seller.\n(c) Notwithstanding anything to the contrary set forth in this Section 2.5, it is the intention of the Parties that the Exploitation of the Compound shall be exercised by Buyer and its Affiliates in accordance with their own business judgment and in their sole and absolute discretion. Accordingly, the following shall apply (and Seller hereby acknowledges, understands and agrees as follows):\n(i) Buyer and its Affiliates shall have complete control and sole discretion with respect to decisions concerning the Exploitation of the Compound and such control and discretion by Buyer and its Affiliates could result in Seller receiving no Milestone Payment whatsoever;\n(ii) neither Buyer nor any of its Affiliates has any duty to Exploit the Compound, to exert any level of efforts in Exploiting the Compound or to achieve the milestone described in Section 2.5(a) above;\n(iii) whether or not Buyer or any of its Affiliates Exploit the Compound, neither Buyer nor any of its Affiliates is prohibited from Exploiting any other compounds or products that may compete with the Compound, or prioritizing other compounds or products over the Compound;\n(iv) personnel of Buyer and its Affiliates are only required to take actions in connection with the Exploitation of the Compound that such personnel believe to be in the best interests of Buyer and its Affiliates and they are not required to take into account the interests of Seller at all; and\n(v) Seller shall not challenge in any subsequent Action any decision regarding the Exploitation of the Compound made by any director, officer, employee or agent of Buyer or any of its Affiliates in what such individual subjectively believes to be the best interests of Buyer (or such Affiliate), unless such Action constitutes a breach by Buyer of any of its express obligations to make the Milestone Payment under this Section 2.5. For the avoidance of doubt, any obligations assumed by Buyer relating to or arising out of the License Agreement shall have no effect on the foregoing provisions of this Section 2.5, and nothing herein, expressed or implied, shall give or be construed to give the Seller or any of its Affiliates any rights as a third party beneficiary of the License Agreement after the Closing.", "snippet_links": [{"key": "terms-and-conditions-of-this-agreement", "type": "clause", "offset": [19, 57]}, {"key": "in-further-consideration", "type": "clause", "offset": [62, 86]}, {"key": "the-sale", "type": "clause", "offset": [90, 98]}, {"key": "buyer-and-seller", "type": "clause", "offset": [173, 189]}, {"key": "buyer-shall", "type": "clause", "offset": [234, 245]}, {"key": "acceptance-of", "type": "definition", "offset": [357, 370]}, {"key": "in-the-united-states", "type": "clause", "offset": [434, 454]}, {"key": "in-writing", "type": "clause", "offset": [512, 522]}, {"key": "days-after", "type": "definition", "offset": [542, 552]}, {"key": "first-milestone-payment", "type": "clause", "offset": [720, 743]}, {"key": "milestone-event", "type": "clause", "offset": [761, 776]}, {"key": "the-license-agreement", "type": "clause", "offset": [800, 821]}, {"key": "notification-to", "type": "clause", "offset": [881, 896]}, {"key": "payment-of-the", "type": "clause", "offset": [905, 919]}, {"key": "seller-shall", "type": "clause", "offset": [941, 953]}, {"key": "transfer-of", "type": "definition", "offset": [970, 981]}, {"key": "immediately-available-funds", "type": "definition", "offset": [982, 1009]}, {"key": "the-account", "type": "clause", "offset": [1013, 1024]}, {"key": "on-schedule", "type": "definition", "offset": [1035, 1046]}, {"key": "by-seller", "type": "clause", "offset": [1091, 1100]}, {"key": "notwithstanding-anything-to-the-contrary", "type": "clause", "offset": [1106, 1146]}, {"key": "the-intention-of-the-parties", "type": "clause", "offset": [1184, 1212]}, {"key": "in-accordance-with", "type": "definition", "offset": [1298, 1316]}, {"key": "business-judgment", "type": "clause", "offset": [1327, 1344]}, {"key": "sole-and-absolute-discretion", "type": "definition", "offset": [1358, 1386]}, {"key": "sole-discretion", "type": "definition", "offset": [1557, 1572]}, {"key": "with-respect-to", "type": "clause", "offset": [1573, 1588]}, {"key": "decisions-concerning-the", "type": "clause", "offset": [1589, 1613]}, {"key": "neither-buyer", "type": "clause", "offset": [1774, 1787]}, {"key": "level-of-efforts", "type": "clause", "offset": [1865, 1881]}, {"key": "other-compounds", "type": "clause", "offset": [2120, 2135]}, {"key": "of-buyer", "type": "clause", "offset": [2262, 2270]}, {"key": "in-connection-with", "type": "clause", "offset": [2324, 2342]}, {"key": "best-interests", "type": "definition", "offset": [2417, 2431]}, {"key": "not-required", "type": "clause", "offset": [2473, 2485]}, {"key": "take-into-account", "type": "definition", "offset": [2489, 2506]}, {"key": "the-interests", "type": "clause", "offset": [2507, 2520]}, {"key": "of-seller", "type": "clause", "offset": [2521, 2530]}, {"key": "subsequent-action", "type": "clause", "offset": [2581, 2598]}, {"key": "employee-or-agent", "type": "definition", "offset": [2686, 2703]}, {"key": "breach-by-buyer", "type": "clause", "offset": [2872, 2887]}, {"key": "express-obligations", "type": "clause", "offset": [2902, 2921]}, {"key": "for-the-avoidance-of-doubt", "type": "clause", "offset": [2976, 3002]}, {"key": "obligations-assumed", "type": "clause", "offset": [3008, 3027]}, {"key": "relating-to", "type": "definition", "offset": [3037, 3048]}, {"key": "arising-out-of", "type": "definition", "offset": [3052, 3066]}, {"key": "provisions-of-this-section", "type": "clause", "offset": [3127, 3153]}, {"key": "the-seller", "type": "clause", "offset": [3236, 3246]}, {"key": "beneficiary-of-the", "type": "clause", "offset": [3300, 3318]}, {"key": "after-the-closing", "type": "clause", "offset": [3337, 3354]}], "size": 6, "hash": "87df5a7a95f0248683c0305ed33df18f", "id": 4}, {"samples": [{"hash": "5SmWispQUD8", "uri": "/contracts/5SmWispQUD8#milestone-payment", "label": "Brand Licensing Agreement", "score": 28.3408622742, "published": true}, {"hash": "bNOQqda7M34", "uri": "/contracts/bNOQqda7M34#milestone-payment", "label": "Brand Licensing Agreement (Minerco Resources, Inc.)", "score": 23.848733902, "published": true}], "snippet": "If at any time the Licensee\u2019s gross sales of Products under the Brands exceeds Twenty-Five Million Dollars ($25,000,000), then Licensee shall pay to Licensor a one-time cash milestone payment equal to One Million Dollars ($1,000,000), payable within thirty days of the end of the first fiscal year in which such gross sales are achieved.", "snippet_links": [{"key": "at-any-time", "type": "clause", "offset": [3, 14]}, {"key": "the-licensee", "type": "definition", "offset": [15, 27]}, {"key": "sales-of-products", "type": "clause", "offset": [36, 53]}, {"key": "licensee-shall", "type": "clause", "offset": [127, 141]}, {"key": "to-licensor", "type": "clause", "offset": [146, 157]}, {"key": "equal-to", "type": "definition", "offset": [192, 200]}, {"key": "thirty-days", "type": "clause", "offset": [250, 261]}, {"key": "first-fiscal-year", "type": "definition", "offset": [280, 297]}], "size": 5, "hash": "541de9894135be936a10f849047d5cf5", "id": 7}, {"samples": [{"hash": "9GPzMH0MM5D", "uri": "/contracts/9GPzMH0MM5D#milestone-payment", "label": "Assignment and Option Agreement (Horizon Pharma PLC)", "score": 26.1553726196, "published": true}, {"hash": "aEf3npDqEik", "uri": "/contracts/aEf3npDqEik#milestone-payment", "label": "Assignment and Option Agreement (Vidara Therapeutics International LTD)", "score": 25.4818611145, "published": true}], "snippet": "InterMune shall pay to Connetics a milestone payment of one million five hundred thousand dollars ($1,500,000), (the \u201cMilestone Payment\u201d), payable in a lump sum or in installments based on the level of InterMune Net Sales, as follows:\n(a) If annualized InterMune Net Sales in the United States for 2001, based on InterMune Net Sales in the United States for the third and fourth calendar quarters of 2001, (\u201c2001 Net Sales\u201d) are equal to or greater than twenty million dollars ($20,000,000), then on March 31, 2002, InterMune shall, at its election, either (i) pay the full Milestone Payment to Connetics, or (ii) pay to Connetics three hundred seventy five thousand dollars ($375,000) of the Milestone Payment and furnish to Connetics a promissory note for the balance of the Milestone Payment, which promissory note shall provide for three (3) principal payments to Connetics of three hundred seventy five thousand dollars ($375,000) each due upon June 30, 2002, September 30, 2002 and December 31, 2002, respectively.\n(b) If 2001 Net Sales are equal to or greater than fifteen million dollars ($15,000,000) but less than twenty million dollars ($20,000,000), then on March 31, 2002, InterMune shall pay to Connetics three hundred thousand dollars ($300,000) of the Milestone Payment, and furnish to Connetics a promissory note for the balance of the Milestone Payment (the \u201cRemaining Payment\u201d), which promissory note shall provide for full payment of the balance of such note to Connetics on the earlier to occur of (i) March 31, 2004, or (ii) the last day of the month following the consecutive twelve (12) month period that InterMune Net Sales in the United States are equal to or greater than twenty million dollars ($20,000,000), subject to subsection (d) below.\n(c) If 2001 Net Sales are less than fifteen million dollars ($15,000,000), then on March 31, 2002, InterMune shall pay to Connetics a portion of the Milestone Payment equal to three hundred thousand dollars ($300,000) multiplied by a fraction, the numerator of which is 2001 Net Sales and the denominator of which is twenty million dollars ($20,000,000). InterMune shall furnish to Connetics a promissory note for the balance of the Milestone Payment (the \u201cRemaining Payment\u201d), which promissory note shall provide for full payment of the balance of such note to Connetics on the earlier to occur of (i) March 31, 2004, or (ii) the last day of the month following the consecutive twelve (12) month period that InterMune Net Sales in the United States are equal to or greater than twenty million dollars ($20,000,000), subject to subsection (d) below.\n(d) With respect to the promissory note for the Remaining Payment described in subsection (b) or (c) above, if InterMune is to pay the balance of such note on March 31, 2004, and InterMune Net Sales in the United States for the twelve (12) month period preceding March 31, 2004 are equal to or greater than ten million dollars ($10,000,000) but less than twenty million dollars ($20,000,000), then:\n(i) InterMune may, at its election, pay fifty percent (50%) of the Remaining Payment either in cash or in Preferred Shares of InterMune stock at the fair market value of such shares, determined as the average closing price of such shares over the previous thirty (30) day period; and\n(ii) With respect to the other fifty percent (50%) of the Remaining Payment, Connetics may, at its election, receive such fifty percent either in cash or in Preferred Shares of InterMune stock at the fair market value of such shares, determined as the average closing price of such shares over the previous thirty (30) day period, provided that Connetics shall notify InterMune of its election in writing at least thirty (30) days prior to the date that such payment is due.\n(e) With respect to the Remaining Payment described in subsection (b) or (c) above, if InterMune is to pay the balance of such note on March 31, 2004, and InterMune Net Sales in the United States for the twelve (12) month period preceding March 31, 2004 are less than ten million dollars ($10,000,000), then InterMune may, at its election, either:\n(1) Pay such Remaining Payment in cash or in Preferred Shares of InterMune stock at the fair market value of such shares, determined as the average closing price of such shares over the previous thirty (30) day period; or\n(2) Grant to Connetics the license to the Accounting and Revenue Rights to CGD Units (as defined below), on commercially reasonable terms to be agreed upon by the Parties, in which event InterMune shall thereafter have no further obligation to Connetics with respect to such Remaining Payment. Such license shall be fully paid-up solely with respect to InterMune but not with respect to Genentech or any other Third Party, and shall expire upon the date of expiration of the last to expire Genentech Patent covering the manufacture, use or sale of Licensed Products for the treatment of CGD in the United States and its territories and possessions. As used herein, \u201cAccounting and Revenue Rights to CGD Units\u201d means the right to book net revenues, expenses and net profits for the sales of Licensed Products for the treatment of chronic granulomatous disease by InterMune and its sublicensees in the United States.\n(f) All promissory notes referred to in this Section 5.2 shall bear interest at the rate of the prime rate plus two percentage points (2%).", "snippet_links": [{"key": "pay-to", "type": "definition", "offset": [16, 22]}, {"key": "lump-sum", "type": "definition", "offset": [152, 160]}, {"key": "based-on", "type": "definition", "offset": [180, 188]}, {"key": "net-sales", "type": "clause", "offset": [212, 221]}, {"key": "sales-in-the-united-states", "type": "clause", "offset": [267, 293]}, {"key": "calendar-quarters", "type": "clause", "offset": [379, 396]}, {"key": "equal-to", "type": "definition", "offset": [429, 437]}, {"key": "on-march", "type": "clause", "offset": [497, 505]}, {"key": "payment-to", "type": "clause", "offset": [584, 594]}, {"key": "five-thousand", "type": "clause", "offset": [653, 666]}, {"key": "furnish-to", "type": "clause", "offset": [715, 725]}, {"key": "balance-of-the", "type": "clause", "offset": [762, 776]}, {"key": "provide-for", "type": "clause", "offset": [824, 835]}, {"key": "payments-to-connetics", "type": "clause", "offset": [856, 877]}, {"key": "remaining-payment", "type": "definition", "offset": [1377, 1394]}, {"key": "payment-of-the-balance", "type": "clause", "offset": [1443, 1465]}, {"key": "note-to", "type": "definition", "offset": [1474, 1481]}, {"key": "day-of", "type": "clause", "offset": [1556, 1562]}, {"key": "following-the", "type": "definition", "offset": [1573, 1586]}, {"key": "subject-to", "type": "clause", "offset": [1737, 1747]}, {"key": "a-portion", "type": "definition", "offset": [1902, 1911]}, {"key": "with-respect-to", "type": "clause", "offset": [2624, 2639]}, {"key": "the-promissory-note", "type": "clause", "offset": [2640, 2659]}, {"key": "to-pay", "type": "clause", "offset": [2744, 2750]}, {"key": "fifty-percent", "type": "definition", "offset": [3059, 3072]}, {"key": "shares-of", "type": "clause", "offset": [3135, 3144]}, {"key": "the-fair-market-value", "type": "clause", "offset": [3164, 3185]}, {"key": "average-closing-price", "type": "clause", "offset": [3220, 3241]}, {"key": "day-period", "type": "definition", "offset": [3287, 3297]}, {"key": "provided-that", "type": "definition", "offset": [3634, 3647]}, {"key": "in-writing", "type": "clause", "offset": [3697, 3707]}, {"key": "prior-to-the", "type": "clause", "offset": [3734, 3746]}, {"key": "payment-is-due", "type": "clause", "offset": [3762, 3776]}, {"key": "payment-in-cash", "type": "definition", "offset": [4149, 4164]}, {"key": "license-to", "type": "clause", "offset": [4375, 4385]}, {"key": "the-accounting", "type": "clause", "offset": [4386, 4400]}, {"key": "revenue-rights", "type": "definition", "offset": [4405, 4419]}, {"key": "terms-to", "type": "definition", "offset": [4480, 4488]}, {"key": "by-the-parties", "type": "clause", "offset": [4504, 4518]}, {"key": "obligation-to", "type": "clause", "offset": [4578, 4591]}, {"key": "fully-paid", "type": "clause", "offset": [4664, 4674]}, {"key": "other-third-party", "type": "definition", "offset": [4752, 4769]}, {"key": "expiration-of-the", "type": "clause", "offset": [4805, 4822]}, {"key": "genentech-patent", "type": "definition", "offset": [4838, 4854]}, {"key": "sale-of-licensed-products", "type": "clause", "offset": [4888, 4913]}, {"key": "treatment-of", "type": "definition", "offset": [4922, 4934]}, {"key": "right-to", "type": "clause", "offset": [5068, 5076]}, {"key": "net-revenues", "type": "definition", "offset": [5082, 5094]}, {"key": "expenses-and", "type": "clause", "offset": [5096, 5108]}, {"key": "net-profits", "type": "definition", "offset": [5109, 5120]}, {"key": "sales-of-licensed-products", "type": "definition", "offset": [5129, 5155]}, {"key": "promissory-notes", "type": "definition", "offset": [5271, 5287]}, {"key": "section-52", "type": "clause", "offset": [5308, 5319]}, {"key": "rate-of", "type": "clause", "offset": [5347, 5354]}, {"key": "the-prime-rate", "type": "definition", "offset": [5355, 5369]}, {"key": "percentage-points", "type": "definition", "offset": [5379, 5396]}], "size": 6, "hash": "909116865350224f60bc2ace14655167", "id": 3}, {"samples": [{"hash": "hMialDa2nLM", "uri": "/contracts/hMialDa2nLM#milestone-payment", "label": "License Agreement (Titan Pharmaceuticals Inc)", "score": 24.1594791412, "published": true}, {"hash": "1GcW7c0YS9P", "uri": "/contracts/1GcW7c0YS9P#milestone-payment", "label": "License Agreement (Titan Pharmaceuticals Inc)", "score": 23.9650917053, "published": true}], "snippet": "The first time Net Sales in the Territory in a Royalty Period exceed *** ***", "snippet_links": [{"key": "first-time", "type": "definition", "offset": [4, 14]}, {"key": "net-sales", "type": "clause", "offset": [15, 24]}, {"key": "in-the-territory", "type": "clause", "offset": [25, 41]}, {"key": "royalty-period", "type": "clause", "offset": [47, 61]}], "size": 4, "hash": "0e05f34796a44fc90d7683fb0ebd4c35", "id": 9}, {"samples": [{"hash": "9ZIRmxf074S", "uri": "/contracts/9ZIRmxf074S#milestone-payment", "label": "Grant Agreement", "score": 36.1544418335, "published": true}, {"hash": "bMSEuARiQe8", "uri": "/contracts/bMSEuARiQe8#milestone-payment", "label": "Grant Agreement", "score": 35.4137001038, "published": true}, {"hash": "6buwgNxAHnQ", "uri": "/contracts/6buwgNxAHnQ#milestone-payment", "label": "Grant Agreement", "score": 35.0941886902, "published": true}], "snippet": "Proposal approved by all parties & submit IRB (delete if no IRB is needed)", "snippet_links": [{"key": "by-all-parties", "type": "clause", "offset": [18, 32]}], "size": 4, "hash": "6cca4468fe4afaf1a7d0a745592e36c0", "id": 8}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhptaWxlc3RvbmUtcGF5bWVudCMwMDAwMDAwYQyiAQJlbhgAIAA=", "clause": {"title": "Milestone Payment", "children": [["development-and-regulatory-milestones", "Development and Regulatory Milestones"], ["milestone-payment-procedures", "Milestone Payment Procedures"], ["milestone-period-income-statement-and-ebitda-calculation", "Milestone Period Income Statement and EBITDA Calculation"], ["dispute-accountants", "Dispute Accountants"], ["payment-of-milestone-payment", "Payment of Milestone Payment"]], "parents": [["consideration", "Consideration"], ["financial-terms", "Financial Terms"], ["payments", "Payments"], ["whereas", "WHEREAS"], ["definitions", "Definitions"]], "size": 400, "id": "milestone-payment", "related": [["milestone-payments", "Milestone Payments", "<strong>Milestone Payments</strong>"], ["sales-milestone-payments", "Sales Milestone Payments", "Sales <strong>Milestone Payments</strong>"], ["milestone", "Milestone", "Milestone"], ["development-milestone-payments", "Development Milestone Payments", "Development <strong>Milestone Payments</strong>"], ["milestone-event-milestone-payment", "Milestone Event Milestone Payment", "Milestone Event <strong>Milestone Payment</strong>"]], "related_snippets": [], "updated": "2026-04-02T05:40:27+00:00", "also_ask": [], "drafting_tip": "Specify milestone criteria and payment amounts to ensure clarity; set deadlines to promote timely performance; require documentation for milestone completion to facilitate verification.", "explanation": "A Milestone Payment clause defines the terms under which payments are made in stages as specific project milestones are achieved. Typically, the contract will outline key deliverables or phases, and upon completion and approval of each, a predetermined payment is released to the service provider. This structure ensures that the client only pays for work that has been completed satisfactorily, while also providing the contractor with regular cash flow, thereby reducing financial risk for both parties and incentivizing timely progress."}, "json": true, "cursor": ""}}